Hematologic Oncology

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss data from the conference that require the most follow-up.

Joshua Richter, MD, of Mount Sinai, and other hematologic cancer experts join CancerNetwork following the 2023 ASH Annual Meeting & Exposition to discuss data from the conference that are most likely to lead to an FDA approval.

Overall, the findings highlight the potential of bispecific antibodies as salvage therapy post anti-CD19 CAR T cell treatment and challenges associated with allogeneic hematopoietic cell transplantation consolidation after bispecific antibodies therapy in patients with relapsed/refractory B-cell lymphomas .

Julie M. Vose, MD, MBA, looks back at 2023 on accomplishments and setbacks surrounding the heamtology/oncology space.

Measures should be taken to encourage more community oncologists to adopt minimal residual disease testing in patients with lymphoid malignancies, according to Georges Azzi, MD, of Holy Cross Health.

In this Cancer Network Around the Practice program, Mazie Tsang, MD offers an overview of the current landscape surrounding frontline therapy in CLL.

Data from a phase 1 study support further analysis of BGB-16673 across several B-cell malignancies, according to the study investigators.

Treatment with NX-2127 leads to clinically meaningful activity in heavily pretreated chronic lymphocytic leukemia, according to results from the phase 1 NX-2127-001 trial.

Investigators of a phase 1 trial identify no safety signals with Orca-Q in the haploidentical stem cell transplantation setting.

Treatment with zanubrutinib may be a viable option for patients with B-cell malignancies who are intolerant to acalabrutinib, says Mazyar Shadman, MD.

Treatment with CAR T cells may allow patients with hematologic malignancies to recover more quickly compared with a transplant, says Andre Goy, MD.

Treatment with ruxolitinib improves the probability of failure-free survival compared with best available treatment among those with chronic graft-versus-host-disease in the phase 3 REACH3 study.

Data from the phase 3 APPLY-PNH trial show comprehensive control of intravascular and extravascular hemolysis with iptacopan in patients with paroxysmal nocturnal hemoglobinuria and persistent anemia.

Phase 2 results showed that the investigational monoclonal antibody axatilimab elicited encouraging clinical activity and tolerability across dose levels in patients with recurrent or refractory chronic graft-vs-host disease.

Retrospective, real-world results showed that oral decitabine and cedazuridine and standard parenteral hypomethylating agents demonstrated similar levels of comorbidities and disease burden in patients with myelodysplastic syndrome.

Older patients with hematological malignancies who received Orca-T therapy plus myeloablative chemotherapy have similar relapse-free survival rates compared with younger patients.

A virtual care platform significantly reduces hospital days for patients who are receiving CAR T-cell therapy, says Tonya Cox, BSN, RN, OCN.

Six BCMA-directed, CD19-directed autologous CAR T-cell therapies are under investigation for the potential risk of T-cell malignancies.

A recent study published in Nucleus discussed the utility of T-cell replete cord blood transplant in patients with high-risk pediatric acute myeloid leukemia and myelodysplastic syndrome.

A recent study published in Nucleus highlighted the impact of graft-vs-host disease prophylaxis on cytomegalovirus reactivation.

Dose adjustments and alternative treatment regimens may be required amid hematologic drug shortages.

Notch signaling acute gastrointestinal graft-vs-host disease was determined in a study analyzing mice and nonhuman primates.

Julie M. Vose, MD, MBA, reflects on the generic drug shortages and the reasoning behind the continued pattern affecting different cancer types.

Resolving disparities within the blood cancer space is a matter of “access to excellent healthcare,” according to Usama Gergis, MD, MBA.

Discrepancies in patients with blood cancer who are eligible for but do not undergo hematopoietic stem cell transplant have been observed not only for Black patients, but Hispanic, Asian, and White patients as well, according to Usama Gergis, MD, MBA.

Nelson J. Chao, MD, MBA, and his colleagues discussed the use of ruxolitinib as treatment for patients with graft-vs-host disease.

Patients with paroxysmal nocturnal hemoglobinuria can now self-administer pegcetacoplan subcutaneously following the FDA’s approval of an injector.

Data from a previous MPN LANDMARK survey highlight that many patients with polycythemia vera experience symptoms that lead to reduced quality of life.

Mohammad Bakri Hammami, MD, highlights a need to address socio-racial disparities among Black and non-Black patients with primary myelofibrosis to ensure that everyone receives high-quality treatment.

Marisol Miranda-Galvis, DDS, MS, PhD, highlights the importance of identifying populations of patients with hematologic cancer who are underserved and using socially targeted solutions.